Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers

Journal of Vascular Surgery

Volumn 44, Issue 4, 2006, Pages 815-819

  Tognazzo, Silvia ^a   Gemmati, Donato ^a   Palazzo, Annunziata ^a   Catozzi, Linda ^a   Carandina, Sergio ^a   Legnaro, Andrea ^a   Tacconi, Giovanna ^a   Scapoli, Gian L ^a   Zamboni, Paolo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 13; HISTIDINE; LEUCINE; PHENYLALANINE; PROLINE; TYROSINE; VALINE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; VEIN DISEASE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; DNA; FACTOR XIII; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; RETROSPECTIVE STUDIES; VARICOSE ULCER; WOUND HEALING;

EID: 33748955977     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.06.006     Document Type: Article

References (28)

1. Abbade L.P., and Lastoria S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol 44 (2005) 449-456
2. Sandeman D., and Shearman C.P. Clinical aspects of lower limb ulceration. In: Mani R., Falanga V., Shearman C.P., and Sandeman D. (Eds). Chronic wound healing. First ed. (1999), W.B. Saunders, London 4-25
3. Thomas D.W., and Harding K.G. Wound healing. Br J Surg 89 (2002) 1203-1205
4. Dardik R., Loscalzo J., and Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 4 (2006) 19-25
5. Vanscheidt W., Hasler K., Wokalek H., Niedner R., and Schopf E. Factor XIII-deficiency in the blood of venous leg ulcer patients. Acta Derm Venereol 71 (1991) 55-57
6. Hildenbrand T., Idzko M., Panther E., Norgauer J., and Herouy Y. Treatment of nonhealing leg ulcers with fibrin-stabilizing factor XIII: a case report. Dermatol Surg 28 (2002) 1098-1099
7. Wozniak G., Dapper F., and Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Semin Thromb Hemost 22 (1996) 445-450
8. Schroder V., and Kohler H.P. Effect of factor XIII Val34Leu on alpha2-antiplasmin incorporation into fibrin. Thromb Haemost 84 (2000) 1128-1130
9. Herouy Y., Hellstern M.O., Vanscheidt W., Schopf E., and Norgauer J. Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. Lancet 355 (2000) 1970-1971
10. Lorenz R., Olbert P., and Born P. Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost 22 (1996) 451-455
11. Nahrendorf M., Hu K., Frantz S., Jaffer F.A., Tung C.H., et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodelling in mice with myocardial infarction. Circulation 113 (2006) 1196-1202
12. Pieber T.R., Schattenberg S., Mostl B., Brunner G.A., Plank J., and Krejs G.J. Treatment of non-healing neuropathic ulcers in the diabetic foot syndrome with factor XIII. Third International Conference on FXIII, Marburg, Germany, Jun 8-9, 1995. Blood Coag Fibrinol 6 (1995) 349
13. Zamboni P., De Mattei M., Ongaro A., Fogato L., Carandina S., De Palma M., et al. Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells. Vasc Endovascular Surg 38 (2004) 431-438
14. Gemmati D., Tognazzo S., Serino M.L., Fogato L., Carandina S., De Palma M., et al. Factor XIII V34L polymorphism modulates the risk of chronic venous leg ulcer progression and extension. Wound Repair Regen 12 (2004) 512-517
15. Kohler H.P., Futers T.S., and Grant P.J. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 81 (1999) 511-515
16. Reiner A.P., Heckbert S.R., Vos H.L., Ariens R.A., Lemaitre R.N., Smith N.L., et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 102 (2003) 25-30
17. Gohel M.S., Taylor M., Earnshaw J.J., Heather B.P., Poskitt K.R., and Whyman M.R. Risk factor for delayed healing and recurrence of chronic venous leg ulcers-An analysis of 1324 legs. Eur J Vasc Endovasc Surg 29 (2005) 74-77
18. Kohler H.P., Ariens R.A., Whitaker P., and Grant P.J. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb Haemost 80 (1998) 704
19. Kangsadalampai S., and Board P.G. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 15 92 (1998) 2766-2770
20. Gemmati D., Serino M.L., Ongaro A., Tognazzo S., Moratelli S., Resca R., et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 67 (2001) 183-188
21. Anwar R., Gallivan L., Edmonds S.D., and Markham A.F. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 93 (1999) 897-905
22. Gallivan L., Markham A.F., and Anwar R. The Leu564 factor XIIIA variant results in significantly lower plasma factor XIII levels than the Pro564 variant. Thromb Haemost 82 (1999) 1368-1370
23. 2 tetramer. Thromb Haemost 82 suppl (1999) 38
24. Adany R., and Bardos H. Factor XIII subunit A as an intracellular transglutaminase. Cell Mol Life Sci 60 (2003) 1049-1060
25. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200 (2003) 448-464
26. Stief T.W. Factor XIII of blood coagulation inhibits the oxidative phagocyte metabolism and suppresses the immune response in vivo. Thromb Res 63 (1991) 227-238
27. Frenkel O., Shani E., Ben-Bassat I., Brok-Simoni F., Rozenfeld-Granot G., Kajakaro G., et al. Activated macrophages for treating skin ulceration: gene expression in human monocytes after hypo-osmotic shock. Clin Exp Immunol 128 (2002) 59-66
28. Yee V.C., Pedersen L.C., Le Trong I., Bishop P.D., Stenkamp R.E., and Teller D.C. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci U S A 91 (1994) 7296-7300